Source study found

Story checked

Possible new target for sickle cell disease and beta thalassemia treatment identified (opens in a new tab)

medicalxpress.com · 2026-09-30

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Possible new target for sickle cell disease and beta thalassemia treatment identified

medicalxpress.com · 2026-09-30

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Three of seven claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

3 supported
4 not covered

Open claim evidence

The source study

Human genetics implicates a BACH2–NRF2 axis in fetal haemoglobin activation

Nature · 2026

Open source record

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredTwo FDA-approved gene therapies reactivate fetal hemoglobin for sickle cell disease and beta thalassemia, and both target BCL11A.View evidenceHide evidence

Why this verdict

The profile mentions BCL11A as an established HbF regulator and reports BACH2/NRF2 effects independent of BCL11A, but it does not state that two FDA-approved gene therapies exist, that they reactivate HbF for sickle cell disease and beta thalassemia, or that both target BCL11A. Those therapy-background details are not verifiable from the supplied abstract-depth paper profile.

Study evidence

Selective editing of overlapping BACH2 and NRF2 motifs in the γ-globin promoters yields opposite effects on γ-globin expression: edits targeting the BACH2-related motif activate γ-globin, whereas edits targeting the NRF2-related motif repress γ-globin.

“Although BACH2 and NRF2 binding motifs in the γ-globin promoters overlap, they can be selectively edited to activate or repress γ-globin, respectively, and do so independently of BCL11A.”

Claim 2 of 7Not coveredIn lab experiments using blood stem cells isolated from bone marrow, inhibiting BACH2 increased fetal hemoglobin levels while overexpressing BACH2 reduced them.View evidenceHide evidence

Why this verdict

The profile supports the core direction that direct perturbation or inhibition of BACH2 increases HbF/γ-globin expression. However, at abstract depth it does not specify use of blood stem cells isolated from bone marrow, nor does it report the reciprocal overexpression experiment reducing HbF. Those experimental specifics cannot be verified from the supplied profile.

Study evidence

Direct perturbation or inhibition of BACH2 increases HbF/γ-globin expression.

“Direct perturbation or inhibition of BACH2 likewise increases HbF expression.”

Claim 3 of 7Not coveredThe authors say pharmacologic inhibition of BACH2 may be another potential route for therapeutic development, and that targeting BACH2-NRF2 together with BCL11A could possibly induce greater fetal hemoglobin production.View evidenceHide evidence

Why this verdict

The underlying biological basis is present: BACH2 inhibition increases HbF/γ-globin, and the pathway is described as independent of BCL11A. But the supplied abstract-depth profile does not verify the authors’ therapeutic-development statement, the quoted safety/effectiveness formulation, or evidence that combined BACH2-NRF2 plus BCL11A targeting could produce greater HbF. The story is appropriately hedged, but the specific translational and combination claims are not verifiable at this depth.

Study evidence

Direct perturbation or inhibition of BACH2 increases HbF/γ-globin expression.

“Direct perturbation or inhibition of BACH2 likewise increases HbF expression.”

Study evidence

“Although BACH2 and NRF2 binding motifs in the γ-globin promoters overlap, they can be selectively edited to activate or repress γ-globin, respectively, and do so independently of BCL11A.”

Claim 4 of 7Not coveredThe article says the first step is determining whether BACH2 can be targeted safely and effectively.View evidenceHide evidence

Why this verdict

The supplied profile supports that the work is mechanistic/in vitro and lacks clinical safety or efficacy evidence, but it does not contain the specific statement that the 'first step' is determining whether BACH2 can be targeted safely and effectively. This is not verifiable from the abstract-level profile.

Claim 5 of 7SupportedHarvard Medical School researchers at Boston Children's Hospital and Dana-Farber Cancer Institute have identified a new pathway that regulates the production of fetal hemoglobin.View evidenceHide evidence

Why this verdict

The supplied abstract-level profile supports identification of a BACH2/NRF2 regulatory mechanism affecting fetal haemoglobin/γ-globin expression, with experimental perturbation and promoter-motif evidence. The institutional affiliation portion is not assessed in the scientific profile, but the headline scientific claim is supported.

Study evidence

Direct perturbation or inhibition of BACH2 increases HbF/γ-globin expression.

“Direct perturbation or inhibition of BACH2 likewise increases HbF expression.”

Study evidence

BACH2 restrains activation of the HbF-encoding γ-globin genes; loss of BACH2 increases NRF2 chromatin occupancy at γ-globin loci and promotes formation of activation foci at those genes, associated with elevated γ-globin/HbF expression.

“Mechanistically, BACH2 restrains activation of the HbF-encoding γ-globin genes, while loss of BACH2 enhances NRF2 chromatin occupancy and promotes the formation of activation foci at the γ-globin genes.”

Claim 6 of 7SupportedThe newly discovered pathway relies on the BACH2 gene and acts independently of BCL11A.View evidenceHide evidence

Why this verdict

The profile supports a newly implicated BACH2-related HbF locus and mechanistic BACH2/NRF2 pathway. It also states that selective promoter-motif effects occur independently of BCL11A, supporting the story’s lead framing.

Study evidence

At a previously uncharacterized HbF-associated locus, the allele rs1010474-C was nominated as a causal, high-HbF–linked variant and is reported to reduce expression of BACH2 while increasing HbF levels.

“In one previously uncharacterized associated region, the high-HbF-linked causal variant rs1010474-C reduces BACH2 expression and elevates HbF levels.”

Study evidence

“Mechanistically, BACH2 restrains activation of the HbF-encoding γ-globin genes, while loss of BACH2 enhances NRF2 chromatin occupancy and promotes the formation of activation foci at the γ-globin genes.”

Claim 7 of 7SupportedThe study, published Sept. 30 in Nature, analyzed fetal hemoglobin levels and related genes in more than 28,000 people from diverse ancestries in a genome-wide association study.View evidenceHide evidence

As statedmore than 28,000 people

Why this verdict

The abstract profile states that the study conducted a multi-ancestry GWAS of HbF levels in 28,279 individuals, which supports the story’s 'more than 28,000' and diverse-ancestry GWAS framing. The exact publication date is not supplied in the scientific units, though the Nature DOI/profile metadata are consistent with publication in Nature.

Study evidence

A multi-ancestry GWAS of HbF (n = 28,279) identified 91 conditionally independent association signals across 12 genomic regions.

“we conduct a large multi-ancestry genome-wide association study of HbF levels in 28,279 individuals that identifies 91 conditionally independent associations across 12 genomic regions.”

Study evidence

“In one previously uncharacterized associated region, the high-HbF-linked causal variant rs1010474-C reduces BACH2 expression and elevates HbF levels.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Fine-mapping/variant-to-gene inference nominating rs1010474-C as a high-HbF-linked causal variant that reduces BACH2 expression and elevates HbF.
The story summarizes BACH2 as part of the pathway but does not describe the specific rs1010474-C variant, fine-mapping evidence, or variant-to-expression inference that materially supports the BACH2 link.
From secondary_data
Experimental limitations: abstract does not specify cell type, exact perturbation/editing methods, replication, quantitative magnitudes, controls, or off-target/on-target editing validation.
The story includes a general caveat that more biology remains and that safe/effective targeting must be established, but it does not mention these interpretation-relevant experimental-detail limitations.
From in vitro; Chromatin-occupancy and nuclear-focus assays (in vitro); in vitro

5 things the story did carry across

Large multi-ancestry GWAS of HbF levels in 28,279 individuals identifying 91 conditionally independent associations across 12 genomic regions.
Experimental perturbation or inhibition of BACH2 increases HbF/γ-globin expression in experimental systems.
Mechanistic model in which BACH2 restrains γ-globin activation, while loss of BACH2 enhances NRF2 chromatin occupancy and activation foci at γ-globin genes.
Selective editing of overlapping BACH2 and NRF2 promoter motifs can activate or repress γ-globin and does so independently of BCL11A.
Translational limitation: the evidence is mechanistic and experimental rather than clinical proof that BACH2 can be safely and effectively targeted as a treatment.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataIdentify genetic determinants of fetal haemoglobin (HbF) levels via a large multi-ancestry GWAS and fine-mapping, including a previously uncharacterized locus implicating BACH2 regulation.multi-ancestry genome-wide association study (GWAS)Expand

In plain English

A large multi-ancestry genome-wide association study of quantitative fetal haemoglobin (HbF) levels in 28,279 individuals identified 91 conditionally independent association signals across 12 genomic regions; one previously uncharacterized region contains a high-HbF–linked variant (rs1010474-C) that is reported to reduce BACH2 expression and associate with elevated HbF.

Key findings

A multi-ancestry GWAS of HbF (n = 28,279) identified 91 conditionally independent association signals across 12 genomic regions.
In one previously uncharacterized associated region, the variant rs1010474-C is reported to reduce BACH2 expression and be associated with elevated HbF.

“we conduct a large multi-ancestry genome-wide association study of HbF levels in 28,279 individuals that identifies 91 conditionally independent associations across 12 genomic regions.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

2secondary dataEstablish that the high-HbF-linked causal variant (rs1010474-C) reduces BACH2 expression and elevates HbF, implicating BACH2 as a functional effector gene.secondary dataExpand

In plain English

The paper reports that fine-mapping at a novel HbF-associated locus nominated rs1010474-C as a high-HbF-linked causal variant; this allele is reported to reduce BACH2 expression and to elevate fetal haemoglobin (HbF) levels.

Key findings

At a previously uncharacterized HbF-associated locus, the allele rs1010474-C was nominated as a causal, high-HbF–linked variant and is reported to reduce expression of BACH2 while increasing HbF levels.

“In one previously uncharacterized associated region, the high-HbF-linked causal variant rs1010474-C reduces BACH2 expression and elevates HbF levels.”

What this piece can’t prove

The abstract does not specify whether the causal-variant nomination for rs1010474-C is supported by independent replication, conditional analyses, or functional allelic assays within this locus.

2 further details could not be confirmed from the summary.

3in vitroDemonstrate experimentally that direct perturbation/inhibition of BACH2 increases HbF/γ-globin expression.Expand

In plain English

Experimental perturbation or inhibition of BACH2 increases fetal haemoglobin (HbF)/γ-globin expression in in vitro/experimental systems.

Key findings

Direct perturbation or inhibition of BACH2 increases HbF/γ-globin expression.

“Direct perturbation or inhibition of BACH2 likewise increases HbF expression.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vitroDefine the mechanism: BACH2 restrains γ-globin activation; loss of BACH2 enhances NRF2 chromatin occupancy and promotes activation foci at γ-globin genes.Chromatin-occupancy and nuclear-focus assays (in vitro)Expand

In plain English

Mechanistic chromatin and nuclear-organization assays reported that BACH2 acts to restrain activation of the HbF-encoding γ-globin genes; loss or reduction of BACH2 increases NRF2 chromatin occupancy at γ-globin loci and promotes formation of activation foci at those γ-globin genes, concomitant with elevated γ-globin/HbF expression.

Key findings

BACH2 restrains activation of the HbF-encoding γ-globin genes; loss of BACH2 increases NRF2 chromatin occupancy at γ-globin loci and promotes formation of activation foci at those genes, associated with elevated γ-globin/HbF expression.

“Mechanistically, BACH2 restrains activation of the HbF-encoding γ-globin genes, while loss of BACH2 enhances NRF2 chromatin occupancy and promotes the formation of activation foci at the γ-globin genes.”

What this piece can’t prove

Abstract lacks information on cell type(s), sample sizes, replication, and quantitative magnitude of the reported changes.

2 further details could not be confirmed from the summary.

5in vitroShow that overlapping BACH2 and NRF2 promoter motifs can be selectively edited to activate or repress γ-globin independently of BCL11A.Expand

In plain English

The authors report that overlapping BACH2 and NRF2 binding motifs in the γ-globin promoters can be selectively edited to produce opposite functional outcomes—editing one motif activates γ-globin while editing the other represses it—and that these motif-specific effects occur independently of the BCL11A regulatory pathway.

Key findings

Selective editing of overlapping BACH2 and NRF2 motifs in the γ-globin promoters yields opposite effects on γ-globin expression: edits targeting the BACH2-related motif activate γ-globin, whereas edits targeting the NRF2-related motif repress γ-globin.
The promoter-motif–specific activation or repression of γ-globin occurs independently of BCL11A.

“Although BACH2 and NRF2 binding motifs in the γ-globin promoters overlap, they can be selectively edited to activate or repress γ-globin, respectively, and do so independently of BCL11A.”

What this piece can’t prove

Summary is based solely on the abstract; the abstract lacks experimental details such as editing modality, cell type, sample size, quantitative results, and statistical analysis.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer